Summit Therapeutics Inc. Income Tax Expense
Summit Therapeutics Inc. (SMMT) reported Income Tax Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxExpenseBenefit · last filed 2026-02-23
- Summit Therapeutics Inc. income tax expense (benefit) for the quarter ending 2021-12-31 was $0.00.
- Summit Therapeutics Inc. income tax expense (benefit) for the quarter ending 2021-09-30 was $0.00.
- Summit Therapeutics Inc. income tax expense (benefit) for the quarter ending 2021-06-30 was $0.00.
- Summit Therapeutics Inc. income tax expense (benefit) for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Summit Therapeutics Inc. income tax expense (benefit) for fiscal 2025 was $0.00.
- Summit Therapeutics Inc. income tax expense (benefit) for fiscal 2024 was $0.00.
- Summit Therapeutics Inc. income tax expense (benefit) for fiscal 2023 was $0.00.
- Summit Therapeutics Inc. income tax expense (benefit) for fiscal 2021 was $0.00.
| Period end | Income Tax Expense (Benefit) 3 month | Income Tax Expense (Benefit) 3 month as first filed | Income Tax Expense (Benefit) 6 month | Income Tax Expense (Benefit) 6 month as first filed | Income Tax Expense (Benefit) 9 month | Income Tax Expense (Benefit) 9 month as first filed | Income Tax Expense (Benefit) 11 month | Income Tax Expense (Benefit) 11 month as first filed | Income Tax Expense (Benefit) 12 month | Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-23 | |||||||||
| 2024-12-31 | $0.00 10-K · filed 2026-02-23 | |||||||||
| 2023-12-31 | $0.00 10-K · filed 2026-02-23 | |||||||||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | $0.00 derived: sum of 2 quarters · filed 2022-12-21 | $0.00 derived: sum of 3 quarters · filed 2022-12-21 | $0.00 10-K/A · filed 2022-12-21 | ||||||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | -$21.00K derived: sum of 4 quarters · filed 2022-12-21 | ||||||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | -$21.00K derived: sum of 3 quarters · filed 2022-12-21 | -$77.00K derived: sum of 4 quarters · filed 2022-12-21 | ||||||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-17 | -$21.00K derived: sum of 2 quarters · filed 2022-12-21 | -$77.00K derived: sum of 3 quarters · filed 2022-12-21 | -$268.00K derived: sum of 4 quarters · filed 2022-12-21 | ||||||
| 2020-12-31 | -$21.00K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | -$77.00K derived: sum of 2 quarters · filed 2022-12-21 | -$268.00K derived: sum of 3 quarters · filed 2022-12-21 | -$213.00K 10-K/A · filed 2022-12-21 | ||||||
| 2020-09-30 | -$56.00K 10-Q · filed 2021-11-15 | -$99.00K 10-Q · filed 2020-11-16 | -$247.00K derived: sum of 2 quarters · filed 2021-11-15 | -$192.00K 10-Q · filed 2021-11-15 | -$93.00K 10-Q · filed 2020-11-16 | |||||
| 2020-06-30 | -$191.00K 10-Q · filed 2021-08-12 | -$136.00K 10-Q · filed 2021-08-12 | $6.00K 8-K · filed 2020-09-29 | |||||||
| 2020-03-31 | $55.00K 10-Q · filed 2021-05-17 | |||||||||
| 2019-12-31 | $36.00K 10-K · filed 2021-03-31 | -$111.00K 8-K · filed 2020-09-29 | ||||||||
| 2019-09-30 | $111.00K 10-Q · filed 2020-11-16 | -$28.00K derived: sum of 2 quarters · filed 2020-11-16 | -$13.00K 10-Q · filed 2020-11-16 | |||||||
| 2019-06-30 | -$139.00K 8-K · filed 2020-09-29 | -$124.00K 8-K · filed 2020-09-29 | ||||||||
| 2019-01-31 | -$1.79M 10-K · filed 2021-03-31 | -$815.00K 8-K · filed 2020-09-29 | ||||||||
| 2018-01-31 | $471.00K 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |